SCHEMBL3660144

SCHEMBL3660144

O=C(c1ccc(OC2CCCSCC2)nc1)N1CCCN(C2CCC2)CC1

nearest known ligand 0.62

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 20/20 0.62
KCNH2 Q12809 4/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL524972 0.97 HRH3 (0.66) HRH3KCNH2
SCHEMBL4137085 0.92 HRH3 (0.72) HRH3KCNH2
SCHEMBL524960 0.91 HRH3 (0.63) HRH3KCNH2
SCHEMBL3660262 0.91 HRH3 (0.70) HRH3KCNH2
SCHEMBL3661975 0.90 HRH3 (0.69) HRH3KCNH2
SCHEMBL3657019 0.90 HRH3 (0.61) HRH3KCNH2
SCHEMBL523885 0.85 HRH3 (0.66) HRH3KCNH2
SCHEMBL525059 0.85 HRH3 (0.66) HRH3KCNH2
SCHEMBL4139077 0.85 HRH3 (0.62) HRH3KCNH2
SCHEMBL4130243 0.85 HRH3 (0.62) HRH3KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883776-B2 Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of the histamine H3 receptor JANSSEN PHARMACEUTICA N.V. (BE) 2014-11-11 US claimed
EP-2222664-B1 CYCLOALKYLOXY- AND HETEROCYCLOALKYLOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2014-10-29 EP claimed
EP-2222664-A1 CYCLOALKYLOXY-AND HET ROCYCLOALKY- LOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR Janssen Pharmaceutica, N.V. (BE) 2010-09-01 EP claimed
WO-2009067401-A1 CYCLOALKYLOXY-AND HETΞROCYCLOALKY- LOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2009-05-28 WO claimed
US-20090131415-A1 CYCLOALKYLOXY-AND HETEROCYCLOALKYLOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2009-05-21 US claimed
EP-3492451-B1 PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2021-11-03 EP disclosed
EP-3492451-A2 PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS Janssen Pharmaceutica NV (BE) 2019-06-05 EP disclosed
EP-3216784-B1 PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2018-12-26 EP disclosed
EP-3216784-A1 PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS Janssen Pharmaceutica NV (BE) 2017-09-13 EP disclosed
EP-2429996-B1 PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2017-03-08 EP disclosed
US-8883776-B2 Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of the histamine H3 receptor JANSSEN PHARMACEUTICA N.V. (BE) 2014-11-11 US disclosed
US-8883776-B2 Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of the histamine H3 receptor JANSSEN PHARMACEUTICA N.V. (BE) 2014-11-11 US disclosed
US-8883776-B2 Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of the histamine H3 receptor JANSSEN PHARMACEUTICA N.V. (BE) 2014-11-11 US disclosed
EP-2222664-B1 CYCLOALKYLOXY- AND HETEROCYCLOALKYLOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2014-10-29 EP disclosed
EP-2222664-B1 CYCLOALKYLOXY- AND HETEROCYCLOALKYLOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2014-10-29 EP disclosed
WO-2009067401-A1 CYCLOALKYLOXY-AND HETΞROCYCLOALKY- LOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2009-05-28 WO disclosed
US-20090131415-A1 CYCLOALKYLOXY-AND HETEROCYCLOALKYLOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2009-05-21 US disclosed
US-20090131415-A1 CYCLOALKYLOXY-AND HETEROCYCLOALKYLOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2009-05-21 US disclosed
US-20090131415-A1 CYCLOALKYLOXY-AND HETEROCYCLOALKYLOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131415-A1 CYCLOALKYLOXY-AND HETEROCYCLOALKYLOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR HRH3, HRH4, HRH1 HRH3 1/4885KCNH2 1285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.